obj blog link, page-13

Longman, its not a GSK thread but I sat in a staff meeting with a GSK SVP (3rd from the throne) in mid December. These are some facts which you can get from 'google'. 1. Pipeline is loaded, with up-to 30 opportunities at phase III in 2011. Similar numbers for 2012. 2. Never been in a better position in history, with greatest number of clinical trials ever, 3. shareprice up 15% for year, or 21% delata versus FTSE.

The unknown for us OBJ holders to me is, will our technology become a part of GSK in 2012? I dont know but I am not concerned as there are so many 'potential opportunities' on the table with multiple global companies. We know drug delivery is the future and with the details we have I am very comfortable to hold and see what materialises.

Best wishes to all in 2012 and gbr, great summation :)